Literature DB >> 11051224

Telomerase RNA as a detection marker in the serum of breast cancer patients.

X Q Chen1, H Bonnefoi, M F Pelte, J Lyautey, C Lederrey, S Movarekhi, P Schaeffer, H E Mulcahy, P Meyer, M Stroun, P Anker.   

Abstract

Tumor-derived circulating DNA has been found in the plasma of cancer patients. Alterations include decreased strand stability, mutations of oncogenes or of tumor suppressor genes, microsatellite alterations, and hypermethylation of several genes. RNA has also been found circulating in the plasma of normal subjects and cancer patients. Tyrosinase mRNA has been extracted from the serum of melanoma patients and subjected to RT-PCR. Moreover, the presence of cell-free EBV-associated RNA has been reported in the plasma of patients with nasopharyngeal carcinoma. Human telomerase comprises two RNA subunits, telomerase RNA template (hTR) and its catalytic component, telomerase reverse transcriptase protein (hTERT). Expression of these subunits correlates with telomerase activity. Using RT-PCR, we investigated whether these RNA subunits were present in the serum of 18 patients with breast cancer, 2 patients with benign breast disease, and 21 normal subjects. The presence of amplifiable RNA was confirmed in all tissue and serum samples using RT-PCR of glyceraldehyde-3-phosphate dehydrogenase RNA. hTR was found in 17 of 18 tumors (94%) and 5 of 18 serum samples (28%). hTERT was also detected in 17 of 18 tumors (94%) and in 4 of 16 available serum samples (25%). hTR and hTERT were undetectable in tissues and sera taken from 2 patients with benign disease and in the sera of 21 normal subjects. We conclude that RNA is detectable in the serum of breast cancer patients and that tumor-derived mRNA can be extracted and amplified using RT-PCR, even in patients with localized disease. This may have implications for cancer diagnosis and follow-up in the future.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11051224

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  67 in total

Review 1.  The detection of circulating breast cancer cells in blood.

Authors:  A M Gilbey; D Burnett; R E Coleman; I Holen
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

Review 2.  Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids.

Authors:  Taisuke Imamura; Shuhei Komatsu; Daisuke Ichikawa; Tsutomu Kawaguchi; Mahito Miyamae; Wataru Okajima; Takuma Ohashi; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Ryo Morimura; Hisashi Ikoma; Kazuma Okamoto; Eigo Otsuji
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

3.  mRNA of placental origin is readily detectable in maternal plasma.

Authors:  Enders K O Ng; Nancy B Y Tsui; Tze K Lau; Tse N Leung; Rossa W K Chiu; Nirmal S Panesar; Lydia C W Lit; Kam-Wing Chan; Y M Dennis Lo
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

4.  A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up.

Authors:  B M Ryan; F Lefort; R McManus; J Daly; P W N Keeling; D G Weir; D Kelleher
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

5.  Extracellular plasma RNA from colon cancer patients is confined in a vesicle-like structure and is mRNA-enriched.

Authors:  José Miguel García; Vanesa García; Cristina Peña; Gemma Domínguez; Javier Silva; Raquel Diaz; Pablo Espinosa; Maria Jesús Citores; Manuel Collado; Félix Bonilla
Journal:  RNA       Date:  2008-05-02       Impact factor: 4.942

6.  A novel biomarker TERTmRNA is applicable for early detection of hepatoma.

Authors:  Norimasa Miura; Yukio Osaki; Miki Nagashima; Michimori Kohno; Kensho Yorozu; Kohei Shomori; Takamasa Kanbe; Kenji Oyama; Yukihiro Kishimoto; Shigeo Maruyama; Eijiro Noma; Yutaka Horie; Masatoshi Kudo; Seigo Sakaguchi; Yasuaki Hirooka; Hisao Ito; Hironaka Kawasaki; Junichi Hasegawa; Goshi Shiota
Journal:  BMC Gastroenterol       Date:  2010-05-18       Impact factor: 3.067

7.  Prognostic impact of clinical course-specific mRNA expression profiles in the serum of perioperative patients with esophageal cancer in the ICU: a case control study.

Authors:  Shunsaku Takahashi; Norimasa Miura; Tomomi Harada; ZhongZhi Wang; Xinhui Wang; Hideyuki Tsubokura; Yoshiaki Oshima; Junichi Hasegawa; Yoshimi Inagaki; Goshi Shiota
Journal:  J Transl Med       Date:  2010-10-22       Impact factor: 5.531

8.  Reduction of Plasma MicroRNA-21 is Associated with Chemotherapeutic Response in Patients with Non-small Cell Lung Cancer.

Authors:  Juan Wei; Lian-Ke Liu; Wen Gao; Cheng-Jun Zhu; Yi-Qian Liu; Ting Cheng; Yong-Qian Shu
Journal:  Chin J Cancer Res       Date:  2011-06       Impact factor: 5.087

Review 9.  Circulating and stool nucleic acid analysis for colorectal cancer diagnosis.

Authors:  Giulia De Maio; Claudia Rengucci; Wainer Zoli; Daniele Calistri
Journal:  World J Gastroenterol       Date:  2014-01-28       Impact factor: 5.742

10.  Prognostic significance of serum ERBB3 and ERBB4 mRNA in lung adenocarcinoma patients.

Authors:  Mirza Masroor; Jamsheed Javid; Rashid Mir; Prasant Y; Imtiyaz A; Mariyam Z; Anant Mohan; P C Ray; Alpana Saxena
Journal:  Tumour Biol       Date:  2015-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.